This guide compares the two at the level of molecule and form, and is clear about what is available now, while not comparing their efficacy as UK fact, because the Wegovy pill is not yet UK-licensed. It is grounded in the UK-licensed products and is general information, not a claim about an unlicensed one.
Different molecules
The first big difference is that these are different active substances14. The Wegovy pill is oral semaglutide, which acts on one receptor, GLP-1; Mounjaro is tirzepatide, which acts on two, GIP and GLP-1 14.
That makes them genuinely different medicines, not two versions of the same one, even though both are used for weight management and both act partly through the GLP-1 system 14. Our guide on how Mounjaro works explains tirzepatide's dual-receptor mechanism 4.
Because they are different molecules, their dosing, and how each behaves, are specific to each medicine and are not interchangeable 14. This is a key difference from the Wegovy pill versus the Wegovy injection comparison, where the molecule is the same 1.
Different forms: oral daily vs weekly injection
The second big difference is the form 4. The Wegovy pill is expected to be an oral daily tablet, while Mounjaro is a weekly injection4. So a comparison would involve both a different molecule and a different route and frequency at once 14.
For routine, that means contrasting a daily tablet with a weekly injection, the same practical trade-off discussed for the pill versus the Wegovy injection, but here with a different molecule on the injection side 4. Needle preference, daily-versus-weekly routine and administration all come into it 14.
As an oral semaglutide, the pill would also carry the absorption-sensitivity point: how it is taken is expected to matter more than for an injection 13. Mounjaro, as a weekly injection, does not depend on that kind of administration timing 4.
What is licensed and available now
The decisive practical point is availability 4. Mounjaro is licensed and available in the UK for weight management in eligible adults today, whereas the Wegovy pill is not yet UK-licensed34.
So for anyone choosing now, Mounjaro is a real option (subject to eligibility and assessment), while the Wegovy pill is not yet something that can be prescribed here 43. That makes the comparison partly forward-looking on the pill's side 3.
Until the pill is licensed, a 'Wegovy pill versus Mounjaro' decision is really 'Mounjaro versus the licensed options that exist now' 4. Any 'Wegovy pill' offered before licensing should be treated as a warning sign, given the NHS warning about fake weight-loss medicines 2.
Want to know when the Wegovy pill (oral semaglutide) becomes available in the UK? It is not yet licensed here, but you can join the waitlist to be notified, and explore the licensed options with a Cloud Pharmacy clinician in the meantime.
Why we don't compare their effectiveness
This guide does not compare the effectiveness of the Wegovy pill and Mounjaro as UK fact 3. Mounjaro has a UK results picture from its licence; the pill does not yet, because it is not UK-licensed, so a head-to-head efficacy claim would go beyond UK sources 43.
Comparing a licensed product with an unlicensed one, using trial data from different studies and populations, can mislead 13. The honest position is to wait for the pill's UK results picture before any such comparison 3.
What can be said is that they are different molecules used for the same broad purpose, and that any difference in outcome would be clarified by the pill's UK licence and assessment rather than assumed now 143. Our guide on Mounjaro and Wegovy compared covers the licensed injections 4.
Side effects and the shared GLP-1 element
Both medicines act partly through the GLP-1 system, and both belong to a class whose common side effects are gastrointestinal, such as nausea, diarrhoea, vomiting and constipation, typically most noticeable early and around dose increases 14. So that general side-effect character is common ground 14.
Both are also used alongside a reduced-calorie diet and increased physical activity, and both are escalated gradually to manage tolerability 14. These shared features come from the GLP-1 element they have in common 14.
The precise side-effect profiles differ by medicine, though, and the pill's own UK profile would come from its licence once approved 34. So while the general character is shared, the specifics are medicine-by-medicine, not assumed across them 43.
How to choose, once both exist
If and when both are available, choosing between them would be a clinical decision based on what suits you: the different molecules, the oral-versus-injection and daily-versus-weekly trade-offs, your eligibility for each, and a prescriber's view of what is appropriate 14. Effectiveness comparisons would draw on the pill's UK results picture once it exists 3.
For now, the practical reality is that Mounjaro and the other licensed options are available and the Wegovy pill is not, so a decision today is among the licensed medicines 42. A prescriber can assess which suits you 4.
The summary is: different molecules, different forms, with only Mounjaro (not the pill) licensed and available in the UK today 143. The pill would add a further option in future, decided with a prescriber on the basis of molecule, form, eligibility and its eventual UK licence 13.
Two differences at once: why this comparison is distinct
It is worth pausing on why this comparison is different from comparing the Wegovy pill with the Wegovy injection 14. There, the molecule is the same and only the form changes; here, both the molecule and the form differ, which makes it a comparison on two axes at once 14.
That matters because it means you cannot reason from one to the other simply 4. Tirzepatide and semaglutide are different substances with their own dosing and their own profiles, so Mounjaro is not 'the injectable version of the Wegovy pill', the way the Wegovy injection is 14. They are separate medicines that happen to share the GLP-1 element 14.
So when weighing them, it helps to keep the two questions separate: which molecule might suit you, and which form suits your life 14. A prescriber can help you think through both, rather than treating them as a single choice 4.
This is also why headline comparisons can be especially misleading here 3. A figure for one molecule in one form, set against a figure for a different molecule in a different form, from different studies, tells you very little reliably, which is another reason to wait for settled UK evidence and a clinician's view 13.
What to do now
Because only the licensed options exist today, the most useful thing now is to consider those with a prescriber rather than waiting on the pill 42. Mounjaro and the other licensed medicines can be assessed for suitability and eligibility right away 4.
If you would specifically prefer an oral form, that is a reasonable preference to note, but it would have to wait for the pill to be licensed, while the injection-based options are available now 13. A prescriber can help you weigh whether to start a licensed option or wait 42.
And if you are not eligible for the licensed options, the pill being a different molecule and form would not automatically change that, since eligibility follows the evidence for each medicine 43. A proper assessment is the way to understand where you stand 42.
So the practical takeaway is to act on what is licensed now if it suits you, stay open to the pill as a future option, and let a prescriber help you compare properly once the UK picture for the pill is settled 143.
The reassuring part is that none of this is a now-or-never decision 1. The licensed options are not going anywhere, and a further option arriving in future does not undo the value of starting something suitable today; a prescriber can always revisit your plan as new licensed choices appear 14. So the absence of the pill from the UK picture right now is not a reason to do nothing, if a licensed option would help you 12. The best course is usually to engage with what is available and proven now, while keeping an eye on what may come, guided throughout by a prescriber who knows your case 14. That way the arrival of a new option becomes a welcome addition to your choices rather than a reason to have waited 13. A prescriber can help you make that judgement in the context of your own circumstances and goals, weighing what is proven and available against what is still to come 14.
Frequently asked questions
Are the Wegovy pill and Mounjaro the same kind of medicine?
They are different molecules: the pill is oral semaglutide (one receptor, GLP-1), Mounjaro is tirzepatide (two receptors, GIP and GLP-1), given by weekly injection 14. Both are used for weight management and act partly through GLP-1 14.What are the main differences?
Different molecules, and different forms: the pill is expected to be an oral daily tablet, Mounjaro is a weekly injection 14. Crucially, Mounjaro is licensed and available in the UK today, while the pill is not yet UK-licensed 34.Which is more effective?
This guide does not compare their efficacy as UK fact, because the pill is not yet UK-licensed and has no UK results picture 43. They are different molecules; any difference would be clarified by the pill's UK licence rather than assumed 1.Can I choose the Wegovy pill instead of Mounjaro now?
No. As of June 2026 Mounjaro is licensed and available in the UK, but the Wegovy pill is not yet UK-licensed 34. Any 'Wegovy pill' offered now is a warning sign, given the NHS warning about fake weight-loss medicines 2.Do they have similar side effects?
Both belong to a class whose common side effects are gastrointestinal, such as nausea, and both are used with diet and activity and escalated gradually 14. The precise profiles differ by medicine, and the pill's would come from its UK licence 34.How should I choose once both are available?
As a clinical decision based on the molecules, the oral-versus-injection and daily-versus-weekly trade-offs, eligibility, and a prescriber's view, with effectiveness from the pill's UK results picture once it exists 143. For now, a decision is among the licensed options 4.Your next step
The Wegovy pill and Mounjaro differ in two big ways at once: they are different molecules, oral semaglutide versus tirzepatide, the latter acting on two receptors rather than one, and they are different forms, an oral daily tablet versus a weekly injection. They share the GLP-1 element, so they have common ground in being used alongside diet and activity, being escalated gradually, and having a broadly gastrointestinal common side-effect character.
The decisive point is that, as of June 2026, Mounjaro is licensed and available in the UK while the Wegovy pill is not yet UK-licensed, so a decision today is among the licensed options rather than between these two. This guide does not compare their efficacy as UK fact, because the pill has no UK results picture yet. If and when both are available, the choice would be a clinical decision based on molecule, form, eligibility and a prescriber's view, and any 'Wegovy pill' offered before UK licensing should be treated as a warning sign.
Disclaimer
This guide is for general information only and does not constitute medical advice, diagnosis or treatment. The information here describes general clinical context based on UK regulatory sources cited above; it is not a recommendation for any specific medicine or treatment, which can only be made by a prescriber following individual assessment.
If you are considering treatment, speak to your GP or pharmacist, or arrange a consultation with a Cloud Pharmacy clinician. Prescription-only medicines are issued only after clinical assessment and where appropriate.
If you experience side effects from any medicine, you can report them through the Yellow Card scheme at yellowcard.mhra.gov.uk.
References
- Wegovy SmPC 4.1/5.1 (semaglutide; GLP-1 receptor; appetite-regulation mechanism; class GI side effects; adjunct to diet and activity; used to describe the pill's molecule via the licensed injection, NOT to assert the pill's efficacy)
- Tirzepatide/semaglutide (registered pharmacy; some websites sell fake weight-loss medicines; used with diet and exercise; general framing)
- General UK framing (June 2026); Wegovy pill not UK-licensed/available; only Mounjaro/licensed options available; NO pill efficacy/dose asserted; deferred to its UK licence
- Mounjaro SmPC 4.1/4.2/5.1 (tirzepatide; dual GIP/GLP-1 receptor agonist; weekly injection; licensed and available for weight management in eligible adults; escalation; GI side effects; adjunct to diet and activity)
